09.18.26 -- Accelerating Gene Therapy & mRNA Manufacturing

Our end-to-end mRNA CDMO platform covers synthesis, LNP formulation, fill-finish, and QC under one roof — from early clinical to commercial scale-up to 100g.

Accelerate cell and gene therapy programs with scalable lentiviral vector manufacturing, delivering high titers, exceptional purity, and reliable clinical supply from gene to clinic.

Achieve accurate, reproducible results in PCR and sensitive molecular workflows with high-purity, enzyme-free water that eliminates contaminants for consistent laboratory performance.

A lifecycle‑based analytical framework supporting release testing, stability studies, and product characterization to boost regulatory readiness, cut variability, and speed development.

Engineered circular DNA formats enabling efficient, low‑toxicity gene editing with high stability, customizable architectures, reduced immune activation, and broad applicability.

A new platform approach streamlines lentiviral vector design and manufacturing, boosting yield, lowering costs, and accelerating access to gene‑modified cell therapies worldwide.

Optimize AAV gene therapy development with construct and process enhancements, boosting titers, potency, and scalability for cost-efficient manufacturing and accelerated timelines.

Cost-effective agarose gel electrophoresis offers reliable plasmid supercoil and host DNA/RNA quantification, providing a practical alternative to qPCR and HPLC for biomanufacturing quality control.

Our mission is clear: to help sponsors reduce costs, shorten timelines, and de-risk development, so they can achieve milestones, secure investments, and advance therapies.

Gain insight into a CDMO with global, end-to-end mammalian manufacturing solutions, proven expertise, flexible capacity, and a strong track record in regulatory compliance.